BCM
REGN icon

Bronte Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bronte Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53M Buy
68,600
+9,300
+16% +$7.12M 5.24% 8
2025
Q4 		$45.8M Buy
+59,300
New +$40.3M 4.57% 8

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bronte Capital Management's REGN Position: Q1 2026 in Review

Bronte Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q1 2026, selling an estimated $3.05M and leaving 172,787 shares worth $134M. The position accounts for 13.22% of the portfolio, ranked #1.

Bronte Capital Management first reported a position in REGN in Q4 2020 and has held it in 22 quarters since. The position peaked at $147M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Bronte Capital Management held 172,787 shares of Regeneron Pharmaceuticals worth $134M as of Q1 2026.
  • Bronte Capital Management sold 3,981 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.05M.
  • Regeneron Pharmaceuticals made up 13.22% of Bronte Capital Management's portfolio in Q1 2026, its #1 holding.
  • Bronte Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Bronte Capital Management's Regeneron Pharmaceuticals position peaked at $147M in Q2 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Bronte Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.